Innovations in SLD Think-Tank: Industry, practitioners and patient advocates translating science into diagnoses, prevention, treatments, and policy. During this two-day intensive, our five roundtables will focus on key areas emphasized in the recent global consensus on research and action priorities: 1. Bridging the Diagnostics Gap: SLD is experiencing cutting-edge advances for testing, accelerated uses for artificial intelligence, and fully scalable industrial solutions for diagnostics. Yet a chasm between increasing prevalence and diagnoses persists. At Innovations we will intensively focus together on bridge-building to cross this diagnosis chasm. 2. Prevention is the ‘Cure’ Hidden in Plain Sight: The socio-economic burden of SLD is growing almost unabated. Yet metabolic dysfunction can be addressed through prevention. Translating clinical evidence into real-world practice and sustaining patient health outcomes remains a steadfast challenge. At Innovations we will ideate next-generation solutions to reinvigorate prevention in the public health policy and SLD practice. 3. The Future of Treatments Now: Hard-fought, not-yet-won MASH pharmacological therapeutics may yet be approved by regulators later this year. Moreover, evidence-based lifestyle interventions remain crucial with - and especially without - drug approvals for patient treatment and care. At Innovations industry, practitioners and patient-advocates will hammer-out immediately actionable steps for what we anticipate being a rapidly evolving treatments landscape for SLD patients, particularly MASH patients. 4. Making Ready Our World Unready: Comorbidity is “growing younger,” yet global policy still ‘thinks’ of non-communicable disease co-morbidities as a condition of aging. We rapidly approach a world in which 1 in 10 people by the age of 18 will present with at least two metabolic associated-dysfunction comorbidities. While policy recognizes diseases and conditions like diabetes, obesity, and hypertension, SLD is under-addressed and in many cases completely absent from public health policy and health systems preparedness. At Innovations industry, practitioners and patient-advocates will discern together both policy-oriented recommendations (e.g., reflect SLD) and operationally necessary actions (e.g., grow the SLD community of practice) to prepare the world, especially health systems, for this growing reality. 5. Targeting Investments for Social and Economic Returns: 2030 fast approaches. Will history report that the Sustainable Development Goals were merely aspirational? Or might the record reflect that a ‘dedicated few’ boldly stepped-forward to path-find targeted choices and scalable paths for the many? At Innovations we will roll-up our sleeves, pull-out our compasses, illustrate best-buy choices and chart paths – some obvious, others unconventional.